References
- United nations. Department of economic and social Affairs, sustainable development. Transforming our world: the 2030 agenda for sustainable development. Sep 2015 [Accessed 2013 Aug]. Available at: https://sdgs.un.org/2030agenda
- Global health Europe: A Platform for European Engagement in Global Health. European Health Values. [Accessed 2023 Aug]. Available at: https://globalhealtheurope.org/values/european-health-values/
- Martin-Moreno J, García-López E, Ballesteros-García I, et al. Health systems in Europe and comparative analysis of criteria for access to innovative diagnostic procedures and therapies in oncology. Informe INESME.(Accessed May 2023) Available at: http://Informe_INESME_Health_Systems_in_Europe.pdf
- Tachkov K, Savova A, Manova M, et al. Tackling reimbursement challenges to fair access to medicines – introduction to the topic. Expert Rev Pharmacoecon Outcomes Res. 2023;2023(6):1–10. doi: 10.1080/14737167.2023.2203384
- Thomson S, Cylus J, Evetovits T Can people afford to pay for health care? New evidence on financial protection in Europe. 2019, WHO. Copenhagen. [Assessed 2023 Jun]. Available at: https://apps.who.int/iris/handle/10665/311654.
- Walshe K, McKee M, McCarthy M, et al. Health systems and policy research in Europe: horizon 2020. Lancet. 2013;382(9893):668–669. doi: 10.1016/S0140-6736(12)62195-3
- World health organization. The world health report 2010 - health systems financing: the path to universal coverage. [Accessed 2023 May] Available at: https://web.archive.org/web/20100820120444/http://www.who.int/whr/2010/en/
- Sawicki P, Bastian H. German health care: a bit of Bismarck plus more science. BMJ. 2008;337(nov07 1):a1997–a1997. doi: 10.1136/bmj.a1997
- Vogler S, Paris V, Ferrario A, et al. How can pricing and reimbursement policies improve affordable access to medicines? Lessons learned from European countries. Appl Health Econ Health Policy. 2017;15(3):307–321. doi: 10.1007/s40258-016-0300-z
- Vogler S, Paris V, Panteli D. Ensuring access to medicines: How to redesign pricing, reimbursement and procurement? [Internet]. In: Richardson E, Palm W, Mossialos E, editors. Eur Observatory On Health Syst Policies. Copenhagen (Denmark): European Observatory on Health Systems and Policies; 2018. PMID: 30272895.
- Vogler S, Paterson KR. Can price transparency contribute to more affordable patient access to medicines? Pharmacoecon Open. 2017;1(3):145–147. doi: 10.1007/s41669-017-0028-1
- Vogler S, Dedet G, Pedersen HB. Financial burden of prescribed medicines included in outpatient benefits package schemes: comparative analysis of co-payments for reimbursable medicines in European countries. Appl Health Econ Health Policy. 2019;17(6):803–816. doi: 10.1007/s40258-019-00509-z
- Schokkaert E, Steel J, Van de Voorde C. Out-of-pocket payments and subjective unmet need of healthcare. Appl Health Econ Health Policy. 2017;15(5):545–555. doi: 10.1007/s40258-017-0331-0
- Vogler S, Schneider P, Dedet G, et al. Affordable and equitable access to subsidised outpatient medicines? Analysis of co-payments under the additional drug package in Kyrgyzstan. Int J Equity Health. 2019;18(1):89. doi: 10.1186/s12939-019-0990-6
- Guindon GE, Fatima T, Garasia S, et al. A systematic umbrella review of the association of prescription drug insurance and cost-sharing with drug use, health services use, and health. BMC Health Serv Res. 2022;22(1):297. doi: 10.1186/s12913-022-07554-w
- McIntyre D, Thiede M, Dahlgren G, et al. What are the economic consequences for households of illness and of paying for health care in low- and middle-income country contexts? Soc Sci Med. 2006;62(4):858–865. doi: 10.1016/j.socscimed.2005.07.001
- Vogler S Payer policies to support innovation and access to medicines in the WHO European region. 2022, World Health Organization. Regional Office for Europe: Denmark Copenhagen, [Assessed 2023 Jun]. Available at: https://apps.who.int/iris/handle/10665/361753.
- Vogler S, Zimmermann N, Haasis MA: PPRI report 2018 - pharmaceutical pricing and reimbursement policies in 47 PPRI network member countries. WHO Collaborating Centre for Pricing and Reimbursement Policies, Gesundheit Österreich GmbH (GÖG/Austrian National Public Health Institute): Vienna, 2019
- Webb E, Richardson E, Vogler S, et al. What are the implications of policies increasing transparency of prices paid for pharmaceuticals? A primer for understanding the policy perspective in light of the empirical evidence. PMID: 36800876. Copenhagen (Denmark): European Observatory on Health Systems and Policies; 2022.
- WHO. Pricing of cancer medicines and its impacts. Geneva: a comprehensive technical report for the World health Assembly resolution 70.12 operative paragraph 2.9 on pricing approaches and their impacts on availability and affordability of medicines for the prevention and treatment of cancer; 2018 [Assessed 2023 Jul]. Available at: https://iris.who.int/bitstream/handle/10665/277190/9789241515115-eng.pdf?sequence=1
- Russo P, Carletto A, Németh G, et al. Medicine price transparency and confidential managed-entry agreements in Europe: findings from the EURIPID survey. Health Policy. 2021;125(9):1140–1145. doi: 10.1016/j.healthpol.2021.06.008
- Chalkidou K, Towse A. Can transparency lower prices and improve access to pharmaceuticals? It depends. JSTOR. 2019;6 [cited2023 May]. Available from: https://www.cgdev.org/sites/default/files/can-transparency-lower-prices-and-improve-access-pharmaceuticals-it-depends.pdf
- Riccaboni M, Van Dyck W, Gyger P, et al. The consequences of greater net price transparency for innovative medicines in Europe: searching for a consensus. CRA. 2020;24:S241. Technical report. doi: 10.13140/RG.2.2.27978.80320/1
- Gamba S, Pertile P, Vogler S. The impact of managed entry agreements on pharmaceutical prices. Health Econ. 2020;29(S1):47–62. doi: 10.1002/hec.4112
- Graham H. Social determinants and their unequal distribution: clarifying policy understandings. Milbank Q. 2004;82(1):101–124. doi: 10.1111/j.0887-378X.2004.00303.x
- Kleinke JD, McGee N. Breaking the Bank: three financing models for addressing the drug innovation cost crisis. Am Health Drug Benefits. 2015;8(3):118–126.
- Tichy EM, Hoffman JM, Tadrous M, et al. National trends in prescription drug expenditures and projections for 2023. Am J Health Syst Pharm. 2023;80(14):899–913. doi: 10.1093/ajhp/zxad086
- Yeong L, Dahye P, Sook K. Determinants of growth in prescription drug spending using 2010–2019 health insurance claims data. Front Pharmacol. 2021;12:1663. doi: 10.3389/fphar.2021.681492
- Kanavos P, Mackenzie M, Cheatley J, et al. Controlling pharmaceutical expenditure and improving efficiency within the Spanish pharmaceutical market. Macro- and micro-level policy approaches. LSE; 2017 [cited 2023 Jun]. Available from: https://eprints.lse.ac.uk/80113/1/Pharmaceutical_Policy_Spain_Priorities_FINAL_LSE_31_05_2018.pdf
- Jakovljevic M, Lazarevic M, Milovanovic O, et al. The New and Old Europe: east-west split in pharmaceutical spending. Front Pharmacol. 2016 Feb 9;7:18.
- Vogler S, Paris V, Ferrario A, et al. How can pricing and reimbursement policies improve affordable access to medicines? Lessons learned from European countries. Appl Health Econ Health Policy. 2017;15(3):307–321. doi: 10.1007/s40258-016-0300-z
- Gerkens S, Merkur S. Belgium: health system review. European Observatory Group. Health syst transit. 2020;22:5.
- Kringos D, Boerma W, Hutchinson A, et al., editors. Building primary care in a changing Europe: case studies [internet]. Copenhagen (Denmark): European Observatory on Health Systems and Policies; 2015. (Observatory Studies Series; 40). https://www.ncbi.nlm.nih.gov/books/NBK459010/
- Gerkens S, Merkur S. Belgium: health system review. Health Syst Transit. 2010;12(5):1–266.
- National People’s Assembly. Health act. Gov newspaper 70; 2004, last amended Gov. newspaper 66, 2023
- National People’s Assembly. Health insurance law. Governmental newspaper 70; June 1998; last amended Governmental newspaper 84; Oct 2023.
- Petmesidou M. Desafios à reforma dos cuidados de saúde na Grécia afetada pela crise. E-Cadernos CES. 2019;31(31). Online. doi: 10.4000/eces.4127
- Jakovlejvich M, Souliotis K. Pharmaceutical expenditure changes in Serbia and Greece during the global economic recession. South East Eur J Public Health. 2016;5(1):1–17. doi: 10.4119/UNIBI/SEEJPH-2016-101
- Editorial. An overview of the healthcare system in Greece. HealthManagement. 2010;10(2):1–2.
- Ministry of Health, Social services and equality. National Health System Of Spain, 2012 [Internet Monograph]. Madrid; 2012 [Assessed 2023 Jul]. Available at: www.msssi.gob.es
- Bernal-Delgado E, García-Armesto S, Oliva J, et al. Spain: health system review. Health Syst Transit. 2018;20(2):1–179.
- Carnicero R, Rojas D, Elicegui I, et al. Proposal of a learning health system to transform the national health system of Spain. Processes. 2019;7(9):613. doi: 10.3390/pr7090613
- Editorial. Overview of the Spanish healthcare system. HealthManagement. 2010;12(5):1–2.
- Przywara B Projecting future health care expenditure at European level: drivers, methodology and main results. European Economy - Economic Papers 2008 – 2015. 2010; 417, Directorate General Economic and Financial Affairs (DG ECFIN), European Commission.
- Sagan A, Thompson S Voluntary health insurance in Europe—country experience, no. 42 (European Observatory on health systems and policies), 2016 [Assessed 2023 Jun]. Available at: http://www.euro.who.int/en/about-us/partners/observatory.
- Ferre F, de Belvis G, Valerio L, et al. Italy: health system review. Health Syst Transit. 2014;16(4):1–168.
- Behmane D, Dudele A, Villerusa A, et al. Latvia: Health system review. Health Syst Transit. 2019;21(4):i–165.
- OECD. OECD Reviews of health systems Latvia. Paris: OECD Publishing; 2016.
- OECD The public health system in Latvia. [Accessed 2023 Apr]. Available at: https://www.oecd-ilibrary.org/sites/9a07e6dc-en/index.html?itemId=/content/component/9a07e6dc-en.
- Likumi lv. Cabinet Regulation No. 330: Vaccine Regulations, 2000. [Accessed 2022 Mar]. Available at: https://likumi.lv/ta/en/en/id/11215.
- Owen L, Fischer A. The cost-effectiveness of public health interventions examined by the national Institute for health and care Excellence from 2005 to 2018. Public Health, 20189. 169:151–162. doi: 10.1016/j.puhe.2019.02.011
- Murauskiene L, Janoniene R, Veniute M, et al. Lithuania: health system review. Health Syst Transit. 2013;15(2):1–150.
- Garuoliene K, Alonderis T, Marcinkevicius M. Pharmaceutical policy and the effects of the economic crisis: Lithuania. Eurohealth. 2011;17:1–4.
- OECD review of health systems, Lithuania 2018, https://www.oecd.org/health/health-systems/OECD-Reviews-of-Health-Systems-Lithuania-2018-Assessment-and-Recommendations.pdf
- Vlădescu C, Scîntee S, Olsavszky V, et al. Romania: health system review. In: health system Reviews. Health Syst Transit. 2016;(18/4):1–170. European Observatory on Health Systems and Policies
- Radu CP, Pana BC, Pele DT, et al. Evolution of public health expenditure financed by the Romanian social health insurance scheme from 1999 to 2019. Front Public Health. 2021;9:795869. doi: 10.3389/fpubh.2021.795869
- Petre I, Barna F, Gurgus D, et al. Analysis of the healthcare system in Romania: a brief review. Healthcare. 2023;11:2069. doi: 10.3390/healthcare11142069
- Healthcare Resource Guide—Romania. [Accessed 2023 Jul]. Available at: https://www.trade.gov/healthcare-resource-guide-romania.
- Petre I, Barna F, Gurgus D, et al. Analysis of the healthcare system in Romania: a brief review. Healthcare. 2023;11(14):2069. doi: 10.3390/healthcare11142069
- Romania: Law no. 95/2006 on Healthcare Reform|European Website on Integration. [accessed 2023 Jul 12]. (Assessed July 2023). Available at: https://ec.europa.eu/migrant-integration/library-document/romania-law-no-952006-healthcare-reform_en.
- Smatana M, Pažitný P, Kandilaki D, et al. Slovakia: Health system review. Health Syst Transit. 2016;18(6):1–210.
- Kapalla M, Kapallová D, Turecký L. An overview of the healthcare system in the Slovak Republic. EPMA J. 2010;1(4):549–561. doi: 10.1007/s13167-010-0061-y
- Slovak Republic. Act no 577/2004 Coll. Of 21 October 2004 on the scope of healthcare covered by public health insurance and on the reimbursement of healthcare-related services, as amended by later regulations.
- Kapalla M. Healthcare information complexity and the role of informatics in predictive, preventive and personalized medicine. In: Niederlag W, Lemke H Rienhoff O, editors Personalisierte medizin und informations technologie. Band 15. Dresden: Health Academy; 2010. p. 83–108.
- Albreht T, Polin K, Pribaković Brinovec R, et al. Slovenia: Health system review. Health Syst Transit. 2021;23(1):i–188.
- Rupel VP, Marušič D. Structure, processes and results in healthcare system in Slovenia. IntechOpen Book; 2021. doi:10.5772/intechopen.98608.
- Albreht T, Klazinga NS. Restructuring public health in Slovenia between 1985 and 2006. Int J Public Health. 2008;53(3):150–159. doi: 10.1007/s00038-008-7032-2
- Petrič VK, Maresso A. Slovenia In: Rechel B, Maresso A Sagan A, et al. editors. Organization and financing of public health services in Europe: country reports: european Observatory on health Systems and policies. 2018. [Assessed 2023 Jul]. (Health Policy Series, No. 49.) p. 9. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507331/
- Or Z, Gandré C, Seppänen AV, et al. France: Health System Review. Health syst transit. 2023Jul;25(3):1–276. PMID: 37489947.
- Nay O, Béjean S, Benamouzig D, et al. Achieving universal health coverage in France: policy reforms and the challenge of inequalities. Lancet. 2016;387(10034):2236–2249. doi: 10.1016/S0140-6736(16)00580-8
- Assurance Maladie, Dossier medical partagé: Le service est désormais disponible pour tous 2018 Nov 6 [Accessed 2023 May]. Available at: https://www.ameli.fr/fileadmin/user_upload/documents/DP_DMP.pdf
- Economie. Médicaments à usage humain. [Assessed 2023 Jul]. Available at: https://economie.fgov.be/fr/themes/ventes/politique-des-prix/prix-reglementes/medicaments-usage-humain
- Panteli D, Arickx F, Cleemput I, et al. Pharmaceutical regulation in 15 European countries. Health Syst Transit. 2016;18(5):1–118.
- Global legal insight. Pricing & Reimbursement Laws and Regulations:Belgium. [Accessed 2023 Aug]. Available at: https://www.globallegalinsights.com/practice-areas/
- Ministry of health. Regulation on prices and reimbursement of medicinal products and inclusion into PDL. Governmental newspaper 40; 2013; last amended Governmental newspaper 28, April 2021г.
- Vardica A, Kontozamanis V PPRI Pharma profile Greece 2007. Pharmaceutical pricing and reimbursement information; commissioned by the European Commission, directorate-general health and Consumer Protection and Austrian Federal Ministry of health, family and youth, 2007
- Economou C, Kaitelidou D, Karanikolos M, et al. Greece: health system review. Health Syst Transit. 2017;19(5):1–192.
- PPRI. [Accessed 2023 Jul]. https://ppri.goeg.at/sites/ppri.goeg.at/files/inline-files
- Vogler S. PPRI pharma brief: spain 2020. Pharmaceutical pricing and reimbursement information (PPRI) pharma briefs series. Vienna: Gesundheit Österreich GmbH (GÖG/Austrian National Public Heatlh Institute); 2020.
- Gallo V, Alessi E, Montilla S, et al. The timelines for the price and reimbursement authorization in Italy 2018–2020. Front Med. 2022;9:1055359. doi: 10.3389/fmed.2022.1055359
- https://www.aifa.gov.it/web/guest/prezzi-e-rimborso. [accessed 2023 Jul
- Voncina L Roadmap for Improving Access to Medicines in Latvia. [Accessed 2023 Jul]. Available at: https://www.vm.gov.lv/lv/media/10082
- TGS Baltic. Regulatory, Pricing and Reimbursement Baltic/Latvia 2021. [Accessed 2023 Aug]. Available at: https://pharmaboardroom.com/legal-articles/regulatory-pricing-and-reimbursement-latvia/
- PPRI. Latvia. Pharmaceutical Pricing And Reimbursement Policies In The In- And Out-Patient Sector. [Accessed 2023 Jul]. Available at: https://ppri.goeg.at/sites/ppri.goeg.at/files/inline-files/Latvia.pdf.
- PPRI. Romania. Pharmaceutical pricing and reimbursement policies in the in- and out-patient sector. [Accessed 2023 Jul]. Available at: https://ppri.goeg.at/sites/ppri.goeg.at/files/inline-files/Lithuania.pdf
- PPRI. Romania: recent and planned developments in pharmaceutical policies 2022/2023. [Accessed 2023 Jul] Available at: https://ppri.goeg.at/system/files/inline-files/PPRI_Cyprus_Romania_2023_0.pdf.
- Musat Associatii, Romania. Regulatory, Pricing And Reimbursement: Romania. 2020 [Accessed 2023 Jul] Available at: https://pharmaboardroom.com/legal-articles/regulatory-pricing-and-reimbursement-romania/
- Ciprian-Paul R, Pana BC, Furtunesku FL. Drug policy in Romania. Value Health Reg Issues. 2018;16:28–32. doi: 10.1016/j.vhri.2017.11.003
- PPRI. Pharmaceutical pricing and reimbursement policies in the in- and out-patient sector. (Assessed 2023 Jul). Available at: https://ppri.goeg.at/sites/ppri.goeg.at/files/inline-files/Slovakia_0.pdf
- Tesar T, Golias P, Masarykova L, et al. The impact of reimbursement practices on the pharmaceutical market for off-patent medicines in Slovakia. Front Pharmacol. 2021;12:795002. doi: 10.3389/fphar.2021.795002
- Psenkova MB, Visnansky M, Mackovicova S, et al. Drug policy in Slovakia. Value Health Reg Issues. 2017;13:44–49. doi: 10.1016/j.vhri.2017.07.002
- https://ppri.goeg.at/sites/ppri.goeg.at/files/inline-files/Slovenia.pdf accessed Jul 2023
- Detiček A, Janzic A, Locatelli I, et al. Decision-making criteria for medicine reimbursement in Slovenia: an expert panel discussion. BMC Health Serv Res. 2018;18(1):1–13. doi: 10.1186/s12913-018-3299-z
- PPRI. Recent and planned developments in pharmaceutical policies 2019. Special topic: patient-based reimbursement decisions. (Assessed 2023 Apr) Available at: https://ppri.goeg.at/sites/ppri.goeg.at/files/inline-files/PPRI_Country_Poster_Tallinn_2019_France_0.pdf
- Tarantola A, Otto MH, Armeni P, et al. Early access programs for medicines: comparative analysis among France, Italy, Spain, and UK and focus on the Italian case. J Of Pharm Policy And Pract. 2023;16(1):67. doi: 10.1186/s40545-023-00570-z
- Emanuel EJ, Zhang C, Glickman A, et al. Drug reimbursement regulation in 6 peer countries. JAMA Intern Med. 2020;180(11):1510–1517. doi: 10.1001/jamainternmed.2020.4793
- Jommi C, Armeni P, Costa F, et al. Implementation of value-based pricing for medicines. Clin Ther. 2020;42(1):15–24. doi: 10.1016/j.clinthera.2019.11.006
- Vassileva M, Kamusheva M, Manova M, et al. Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria. Expert Rev Pharmacoecon Outcomes Res. 2019;19(6):733–742. doi: 10.1080/14737167.2019.1592680
- OECD. Healthcare quality and outcomes indicators. (Assessed 2022 Apr) Available at: https://www.oecd.org/health/health-systems/health-care-quality-outcomes-indicators.htm
- National statistical institute of Bulgaria. www.nsi.bg
- Mold J. Goal-directed health care: Redefining health and health care in the Era of value-based care. Cureus. 2017 Feb 21;9(2):e1043. doi: 10.7759/cureus.1043
- Lehoux P, Roncarolo F, Silva HP, et al. What health system challenges should responsible innovation in health address? Insights from an international Scoping review. Int J Health Policy Manag. 2019;8(2):63–75. doi: 10.15171/ijhpm.2018.110
- Koplan JP, Fleming DW. Current and future public health challenges. JAMA. 2000;284(13):1696–1698. doi: 10.1001/jama.284.13.1696
- Fontrier AM, Visintin E, Kanavos P. Similarities and differences in health technology assessment systems and implications for coverage decisions: evidence from 32 countries. PharmacoEconomics-Open. 2022;6(3):315–328. doi: 10.1007/s41669-021-00311-5
- García-Mochón L, Balbino JE, de Labry Lima AO, et al. HTA and decision-making processes in central, eastern and Southeastern Europe: results from a survey. Health Policy. 2019;123(2):182–190. doi: 10.1016/j.healthpol.2017.03.010
- Kaló Z, Gheorghe A, Huic M, et al. HTA implementation roadmap in central and Eastern European countries. Health Econ. 2016;25(S1):179–192. doi: 10.1002/hec.3298
- EC. Regulation (EU) 2021/2282 of the European Parliament and of the council of 15 December 2021 on health technology assessment and amending directive 2011/24/EU. OJ L 458, 22.12.2021.
- Dylst P, Vulto A, Simoens S. Analysis of European policy towards generic medicines. GaBi J. 2014;3(1):34–35. doi: 10.5639/gabij.2014.0301.011
- European Commision. State of health – country profiles, available at: country health profiles (europa.Eu), ( Accessed 03.09.2023)
- Wouters OJ, Kanavos PG. A comparison of generic drug prices in seven European countries: a methodological analysis. BMC Health Serv Res. 2017;17(1):242. doi: 10.1186/s12913-017-2184-5
- Wagner JL, McCarthy E. International differences in drug prices. Annu Rev Public Health 2004. 2004;25(1):475–495. doi: 10.1146/annurev.publhealth.25.101802.123042
- OECD Health Statistics. 2016 - Frequently Requested Data. Oct 2016. [Assessed 2023 Apr]. Available online: http://www.oecd.org/els/health-systems/oecd-health-statistics-2014-frequently-requested-data.htm
- OECD. Health policy studies. Value for money in health spending. Paris: OECD Publishing; 2010.
- Peiró M, Barrubés J. New context and old challenges in the healthcare system. Rev Esp Cardiol. 2012;65(7):651–5. doi: 10.1016/j.rec.2012.02.018
- Kickbusch I, Gleicher D. Governance for health in the 21st century. Geneva: World Health Organization; 2012.